Hospital  >  News & media  >  News

A common diabetes medication may slow memory decline in Alzheimer's disease

July 29, 2020


A new study from researchers at Sunnybrook Research Institute and the University of Toronto has shown that a common diabetes medication may have the potential to slow memory loss in patients with Alzheimer’s disease.

The research team found that the rate of memory decline was slower in people with Alzheimer’s disease taking a specific class of anti-diabetic drug, known as a dipeptidyl peptidase-4 (DPP4) inhibitor. The findings were presented at the Alzheimer's Association International Conference today and will be published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

“We know that type 2 diabetes is a risk factor for Alzheimer’s disease. It has also been suggested that anti-diabetic drugs may be of benefit, but the clinical evidence has been limited and mixed”, says Dr. Walter Swardfager, senior author of the study and scientist in the Hurvitz Brain Sciences Program at Sunnybrook Research Institute. “The mechanisms behind DPP4 inhibitors ​point towards new potential to prevent and slow the progression of Alzheimer’s disease.”

The observational study analyzed patients from 37 sites across the U.S. who had been treated with an anti-diabetic medication and had either Alzheimer’s disease dementia or normal cognition. In total, 807 patients with Alzheimer’s dementia and 1,192 patients with normal cognition were studied. All patients had type 2 diabetes, and their memory was assessed with a standardized recall test.

“To our knowledge, this study offers the first evidence that DPP4 inhibitor use may be of benefit to memory in people with Alzheimer's disease.” says Che-Yuan (Joey) Wu, lead author of the study and a graduate student in the Department of Pharmacology & Toxicology at the University of Toronto.

Among cognitively normal older people, a greater benefit of the DPP4 inhibitors was found among those who carry the ApoE ε4 gene, a well-known genetic risk factor for Alzheimer's disease.

The authors emphasize that the results from this study and future research have implications for the personalized prevention and treatment of Alzheimer's disease among people with type 2 diabetes. “This initial analysis could help guide clinical trials and inform studies examining the benefits of DPP4 inhibitors,” says Che-Yuan (Joey) Wu. “These studies could further support DDP4 inhibitors as a potential therapeutic strategy for Alzheimer's disease prevention and treatment.”

This research received funding from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, The Alzheimer’s Association (US), Brain Canada, the Michael J. Fox Foundation, Weston Brain Institute, and Alzheimer’s Research UK. The National Alzheimer’s Coordinating Center, which is funded by National Institute on Aging/National Institute of Health (US), provided data for this research.

Media contact:
Samantha Sexton
Communications advisor